FDA Approves Abbott's Atrial Fibrillation Device For LAA Occlusion

by Vandana Singh, Benzinga Editor

August 16, 2021 3:09 PM | 1 min read | Make a Comment

The FDA has approved Abbott Laboratories' ABT Amplatzer Amulet Left Atrial Appendage Occluder to treat people with atrial fibrillation (AFib) who are at risk of ischemic stroke.
The device offers immediate closure of the left atrial appendage (LAA), where blood clots can form in people suffering from AFib, reducing their risk of stroke and immediately eliminating the need for blood-thinning medication.
Related content: Benzinga's Full FDA Calendar
The LAA is a small pouch connected to the upper left chamber of the heart.
Price Action: ABT shares are up 0.98% at $124.25 during the market session on the last check Monday.

Posted In: News Health Care FDA General Atrial Fibrillation Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.